57 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2035. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2035
Next term end
34
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2037 · High confidence
Also notable
Ends Jul 2038 · High confidence
Also notable
Ends Aug 2038 · High confidence
Compounds, Compositions and Methods
US 9,815,850
The most cited patent in this portfolio, cited by 79 later US patents, top 5% of utility patents granted in 2017 in our data. Protection runs to 2037.
Engineered Transferrin Receptor Binding Polypeptides
US 11,795,232
Cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2038.
Modulators of Eukaryotic Initiation Factor 2B, Compositions and Methods
US 11,236,100
Cited by 6 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Phospho-Rab Antibodies, Assays and Methods of Use Thereof (US 11,661,461) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 2 fees due Feb 6 to 22, 2027 · next Feb 6
- 3 fees due Apr 3 to 29, 2027 · next Apr 3
- 5 fees due Jun 5 to 26, 2027 · next Jun 5
- 2 fees due Jul 9 to 30, 2027 · next Jul 9
- 1 fee due Aug 27, 2027The maintenance fee for Methods of Engineering Transferrin Receptor Binding Polypeptides (US 11,912,778) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 2 fees due Sep 17 to 30, 2027 · next Sep 17
- 1 fee due Oct 16, 2027The maintenance fee for Compounds, Compositions and Methods (US 11,958,840) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
What they patent
The 5 largest of its 34 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compounds, Compositions, and Methods | 6 in force | to Mar 2038 |
| Compounds, Compositions and Methods (2017) | 5 in force | to Feb 2037 |
| Polymorphs and Solid Forms of a Pyrimidinylamino-Pyrazole Compound, and Methods of Production | 3 in force | to Nov 2038 |
| Engineered Transferrin Receptor Binding Polypeptides | 3 in force | to Jul 2038 |
| Compounds, Compositions and Methods (2019) | 2 in force | to Feb 2040 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,771,378 | Fused Morpholinopyrimidines and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 9,802,927 | Oxadiazine Compounds and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,214,565 | Compound, Compositions, and Methods In force · High confidence | In force | High confidence | |
| US 9,815,850 | Compounds, Compositions and Methods In force · High confidence | In force | High confidence | |
| US 9,896,458 | Compounds, Compositions and Methods In force · Medium confidence | In force | Medium confidence | |
| US 10,131,676 | Compounds, Compositions and Methods In force · High confidence | In force | High confidence | |
| US 10,604,535 | Compounds, Compositions and Methods In force · High confidence | In force | High confidence | |
| US 12,358,928 | Compounds, Compositions and Methods In force · Medium confidence | In force | Medium confidence | |
| US 11,028,080 | Substituted Pyrimidines as LRKK2 Inhibitors In force · High confidence | In force | High confidence | |
| US 11,840,529 | Substituted Pyrimidines as LRKK2 Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 57: 1 patent in force now held by others · 52 applications pending · 42 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.